Close menu




September 28th, 2021 | 11:19 CEST

Cardiol Therapeutics, BioNTech, Valneva - Volatility offers good opportunities!

  • Biotechnology
Photo credits: pixabay.com

The share prices of the Corona vaccine manufacturers are not growing sky-high after all. Most recently, developments at France's Valneva caused uncertainty. The French Company wanted to bring a Corona vaccine to market by the end of 2021 and had already received an order from the British government for 100 million units. This contract has now been canceled. Where does the industry go from here?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CARDIOL THERAPEUTICS | CA14161Y2006 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    CARDIOL THERAPEUTICS INC - The first stage has ignited

    Cardiol Therapeutics is breaking new ground in the therapy of inflammatory heart disease. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that cites the use of cannabidiol as beneficial as an anti-inflammatory agent.

    The Company's lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is currently being evaluated in a Phase II/III outcomes study in hospitalized patients who tested positive for the COVID-19 virus. This potentially pivotal study is designed to assess the efficacy and safety of CardiolRx as a cardioprotective therapeutic to reduce mortality and major cardiovascular events in COVID-19 patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease.

    Cardiol has received FDA approval for its investigational new drug application for an international Phase II study. It will evaluate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the leading cause of sudden cardiac death in people under the age of 35. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies to treat chronic heart failure - a leading cause of death and hospitalization in North America.

    The Company's shares have been listed on NASDAQ since August 10. Inclusion in the US index has led to a significant surge in the share price. Since the start of trading, the stock has doubled to around CAD 5.70. The Company is thus worth CAD 244 million. According to the analysts at GBC, the share still has significant room for improvement. The experts formulate a target price of CAD 17.49.

    BIONTECH SE - EMA decision expected

    The share has corrected by about a quarter since mid-August. Operationally, everything is in order; trend-setting decisions have been made in the USA, which are expected shortly in Europe. In terms of valuation, the stock is also in the green zone. In the future, the mRNA technology on which the Corona vaccine was developed could be extended to other areas of application, such as cancer. For the moment, however, the negative sector sentiment is outweighed by developments at France's Valneva.

    The US Food and Drug Administration (FDA) recently approved booster vaccinations with BioNTech/Pfizer's Corona vaccine for the elderly and high-risk groups. It applies to people 65 years of age and older and people between 50 and 64 years of age who belong to risk groups. The booster vaccines are to be administered at least six months after the first two vaccinations. Case-based testing will also allow people 18 and older who belong to at-risk groups to receive booster vaccinations.

    A few days ago, the Germans applied to the European regulatory authority EMA to consider a so-called blanket booster vaccination. The idea is to provide a third vaccination for fully vaccinated people over the age of 16. The EMA plans to issue its recommendation in early October. If the EMA decision is favorable and booster vaccinations increase worldwide, the share price should soon rise again.

    With a share price of around USD 320, BioNTech is currently valued at USD 80 billion. Analysts forecast earnings in the range of USD 11 billion each this year and next, making the stock moderately valued with a P/E ratio of 8.

    VALNEVA SE - Where do we go from here?

    In mid-September, Valneva shareholders received a massive shock. The British government canceled the supply contract in the volume of 100 million doses of the Corona vaccine, which is still in development. The British accuse the French of breaching the contract, which the latter vehemently deny. According to the Company, the vaccine is currently in Phase 3 trials. Further clinical trial data is expected to be published in Q4, and initial approval of the vaccine is possible by the end of 2021.

    The news comes as a surprise also because the vaccine is well tolerated and has few, at least known, side effects, which generally underline the advantages of a classic inactivated vaccine over mRNA gene therapeutics. Now that the share price has corrected significantly and the valuation has melted down to EUR 1.3 billion, the negative information should have been processed in the share price.


    After CureVac, Valneva now shocked the markets. Industry sentiment is depressed. Declining prices at BioNTech offer opportunities. Valneva's share price should have found its bottom. Cardiol has excellent potential with its innovative solutions, and the listing on NASDAQ has already had a positive impact.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Stefan Feulner on January 12th, 2023 | 14:33 CET

    Powerful movements in the biotech sector - CureVac, Cardiol Therapeutics, Ambrx Biopharma

    • Biotechnology
    • Covid19
    • Cancer

    That the biotech sector stands for high volatility is nothing new. Price jumps of more than 50% in one day after study results are no exception. Last year, the capital-intensive sector of the future suffered from the change in strategy by the central banks with several interest rate hikes. The Nasdaq Biotech Index alone lost around 50% of its value in some cases. In addition, smaller stocks that do not yet have a commercial product on the market experienced massive upheavals. The speed with which a rebound can set in was demonstrated not only by vaccine producer CureVac.

    Read

    Commented by Armin Schulz on January 9th, 2023 | 17:35 CET

    BioNTech, Defence Therapeutics, Bayer - Is a Corona tsunami imminent?

    • Biotechnology
    • Covid19
    • Cancer

    At the beginning of December, things were quiet concerning Corona. The feared wave failed to materialize, and there were no new variants. On December 7, China announced a relaxation of Corona measures. Now the country is facing a gigantic Corona wave. Many European countries have already imposed mandatory testing for entry from China. Germany has now followed suit. In parallel, the Consumer Electronics Show 2023 ran from the 5th to the 8th in Las Vegas, where all kinds of companies from all over the world presented their latest technology. Chinese companies also exhibited there. Because of the multitude of infections, new deadly mutations could emerge. As a result, pharmaceutical and biotech companies are coming back into focus.

    Read

    Commented by André Will-Laudien on January 5th, 2023 | 06:35 CET

    It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?

    • Biotechnology
    • Covid19
    • Cancer

    The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.

    Read